Orphan Medical Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Minnetonka MN United States (1994)
Status: Acquired by Jazz Pharmaceuticals (2005)

Organization Overview

First Clinical Trial
2000
NCT00049803
First Marketed Drug
1998
sacrosidase (sucraid)
First NDA Approval
1998
sacrosidase (sucraid)
Last Known Activity
2003

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Marketed Drugs (3)

betaine (NDA)

sacrosidase (sucraid) (1998 NDA)

sodium oxybate (xyrem) (2002 NDA)

Drugs in Phase 3 Trials (1)

sodium oxybate (xyrem) (2 trials)

Drugs in Phase 2 Trials (1)

betaine (1 trial)

Drugs in Phase 1 Trials (2)

pentobarbital (nembutal) (1 trial)

triazolam (halcion) (1 trial)

Indications

Approved Indications


 

Depressive Disorder

Homocystinuria

Narcolepsy

Sleep Initiation and Maintenance Disorders

Experimental Indications (Clinical Trials, Phases 1-4)


 

Fatty Liver (Phase 2)

Narcolepsy (Phase 3)

Non-alcoholic Fatty Liver Disease (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 3
  • # of Trial APIs: 4